Androgen insensitivity syndrome medical therapy

Jump to navigation Jump to search

Androgen insensitivity syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Androgen insensitivity syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Androgen insensitivity syndrome medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Androgen insensitivity syndrome medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Androgen insensitivity syndrome medical therapy

CDC on Androgen insensitivity syndrome medical therapy

Androgen insensitivity syndrome medical therapy in the news

Blogs on Androgen insensitivity syndrome medical therapy

Directions to Hospitals Treating Androgen insensitivity syndrome

Risk calculators and risk factors for Androgen insensitivity syndrome medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]

Overview

A multidisciplinary approach is recommended for clinical management from infancy through to adulthood. Hormone replacement therapy is needed following gonadectomy. Patients who choose to retain the gonads are at risk of developing germ cell tumors for which sensitive circulating tumor markers may soon become available. [1]

Medical Therapy

General management

Management of androgen insensitivity syndrome should address: [2]

    • Functional issues
    • Sexual issues
    • Psychological issues such as disclosure
    • Gonadectomy and subsequent hormone replacement
    • Creation of a functional vagina, and provision of genetic advice.
    • Care needs to be individualised, flexible, and holistic.
    • Management is dependent wholly on a multidisciplinary team.

References

  1. Mongan NP, Tadokoro-Cuccaro R, Bunch T, Hughes IA (2015). "Androgen insensitivity syndrome". Best Pract Res Clin Endocrinol Metab. 29 (4): 569–80. doi:10.1016/j.beem.2015.04.005. PMID 26303084.
  2. Hughes IA, Davies JD, Bunch TI, Pasterski V, Mastroyannopoulou K, MacDougall J (2012). "Androgen insensitivity syndrome". Lancet. 380 (9851): 1419–28. doi:10.1016/S0140-6736(12)60071-3. PMID 22698698.

Template:WH Template:WS